Cyanophycin: Physiology and What Research Reports
Cyanophycin is a non-ribosomal amino acid polymer — multi-L-arginyl-poly-L-aspartate — made by cyanobacteria and some other bacteria as an intracellular nitrogen store. Cyanophycin synthetase builds it from aspartate and arginine, and cyanophycinases break it back down into β-Asp-Arg dipeptides. It is not produced by humans and is not a signalling peptide. The verified literature on it is structural, microbiological and biotechnological: enzyme mechanisms, production platforms and biomaterial or scaffolding applications, rather than human dosing studies.
What cyanophycin is
Cyanophycin, also written as multi-L-arginyl-poly-L-aspartate or CGP, is a polymer of just two amino acids: a poly-aspartate backbone in which each aspartate side chain carries an arginine attached through an isopeptide bond, a structure described in a 2023 review of cyanophycin and its biosynthesis (PMID 37231979). Because it is assembled by dedicated enzymes rather than on the ribosome, it is not a gene-encoded peptide sequence, and reviewers have grouped it with other non-ribosomal amino acid polymers produced by microbes (PMID 31095967). In producing cells the polymer is reported to accumulate as insoluble intracellular granules that can be released and recovered by laboratory extraction (PMID 37231979).
Where it is produced and what it does in the producing organism
Cyanophycin is a microbial product. The 2023 review reported that it is synthesised by cyanobacteria and by a range of other bacteria, where it functions as a dynamic store of nitrogen and carbon that is laid down when nitrogen is plentiful and mobilised when it is not (PMID 37231979). A 2025 study in The Journal of Biological Chemistry reported that cyanophycinase — the enzyme that degrades the polymer — is required for heterotrophy in cyanobacteria, linking breakdown of the granule to growth on organic carbon (PMID 41062069). Turnover also happens outside the cell: researchers isolated cyanophycin-degrading bacteria from the environment and cloned cphE, an extracellular cyanophycinase gene, from Pseudomonas anguilliseptica strain BI (PMID 11986309).
Readers who meet the word in a peptide context should note what the literature does not say: humans do not make cyanophycin. It is not a hormone, a growth factor or a signalling peptide, and the verified papers describe it as a bacterial storage polymer and a feedstock or biomaterial rather than an endogenous human molecule (PMID 37235756).
The enzymes that build and break it
Cyanophycin synthetase
A 2021 study in Nature Chemical Biology reported structures and function of cyanophycin synthetase (CphA1), the ATP-dependent amino acid polymerase that adds aspartate and arginine to the growing chain in separate catalytic sites (PMID 34385683). A 2022 Nature Communications paper reported structural bases for aspartate recognition and for the polymerisation efficiency of a cyanobacterial cyanophycin synthetase, explaining how the enzyme selects its backbone substrate (PMID 36042318). Some organisms instead use a second enzyme class: researchers described the structure and function of cyanophycin synthetase 2 (CphA2) as a β-Asp-Arg polymerase that assembles the polymer from preformed dipeptide units (PMID 35179888).
Cyanophycinase
Degradation runs through cyanophycinases. A 2022 structural study captured cyanophycinase in complex with a cyanophycin degradation intermediate, reported as a view of how the enzyme processes the chain toward β-Asp-Arg dipeptides (PMID 35905922). The extracellular counterpart encoded by cphE was reported to hydrolyse cyanophycin outside the cell (PMID 11986309), and the 2025 physiology study tied intracellular cyanophycinase activity to the ability of cyanobacteria to grow heterotrophically (PMID 41062069).
| Term | What the literature describes | Example source |
|---|---|---|
| Cyanophycin / CGP | Poly-aspartate backbone with arginine on each side chain; insoluble storage granules | PMID 37231979 |
| CphA1 | ATP-dependent synthetase adding Asp and Arg in separate active sites | PMID 34385683 |
| CphA2 | β-Asp-Arg polymerase that builds the polymer from dipeptides | PMID 35179888 |
| CphB / cyanophycinase | Intracellular hydrolase; reported as required for heterotrophy in cyanobacteria | PMID 41062069 |
| CphE | Extracellular cyanophycinase cloned from P. anguilliseptica BI | PMID 11986309 |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow cyanophycin is measured and studied
Most of the verified work falls into three methodological families. First, structural biology of the enzymes, where researchers solved synthetase and cyanophycinase structures with substrates or reaction intermediates bound (PMID 36042318, PMID 35905922). Second, microbial physiology and genetics, in which deletion or characterisation of the degrading enzyme was reported to change how cyanobacteria use stored nitrogen and organic carbon (PMID 41062069). Third, production and analysis: a 2019 review in Biotechnology Advances covered microbial production of cyanophycin from enzymes through to isolated biopolymer, including recombinant expression and recovery of the granules (PMID 31095967). Plant systems have also been tested; a 2016 study examined tobacco as a platform for commercial production of cyanophycin (PMID 27501906).
Why it matters to peptide-adjacent reading
Cyanophycin appears in peptide literature for two reasons. It is a natural example of peptide-bond polymer chemistry built without a ribosome, which makes its synthetases interesting as enzymatic tools for making defined amino acid polymers (PMID 34385683). It is also studied as a material and as a source of arginine- and aspartate-rich building blocks: a 2023 paper in Macromolecular Bioscience reported recombinant multi-L-arginyl-poly-L-aspartate as an emerging biomaterial (PMID 37235756), and a 2021 review reported chemical and enzymatic modifications aimed at widening its application potential (PMID 34738009). A 2024 paper in Applied Microbiology and Biotechnology reported cyanophycin modifications intended for use in tissue scaffolding (PMID 38489042).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appHuman Exposure and Safety: What Studies Report
Within the verified literature summarised here, the reported work is enzymological, microbiological and materials-focused. The 2024 scaffolding study reported modified cyanophycin preparations evaluated for material applications rather than as an administered therapeutic (PMID 38489042), and the 2023 biomaterial review discussed recombinant cyanophycin in the context of production and processing (PMID 37235756). None of these sources reported human dosing trials, adverse-event frequencies or clinical outcomes for cyanophycin, so no such figures are presented on this page. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything related to health, supplements or medicines.
Limitations of the current picture
- The physiological role is described for microbes, not for humans; no endogenous human pathway was reported in these sources (PMID 37231979).
- Structural studies explain catalysis but do not establish biological effects in animals (PMID 35179888).
- Production yields and polymer composition vary by host and process, which reviewers reported as a practical constraint on applications (PMID 31095967, PMID 27501906).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Cyanophycin and its biosynthesis: not hot but very cool (Natural Product Reports, 2023)
- Cyanophycin modifications for applications in tissue scaffolding (Applied Microbiology and Biotechnology, 2024)
- Structure and Function of the β-Asp-Arg Polymerase Cyanophycin Synthetase 2 (ACS Chemical Biology, 2022)
- Cyanophycinase is required for heterotrophy in cyanobacteria (The Journal of Biological Chemistry, 2025)
- Structures and function of the amino acid polymerase cyanophycin synthetase (Nature Chemical Biology, 2021)
- Recombinant Multi-l-Arginyl-Poly-l-Aspartate (Cyanophycin) as an Emerging Biomaterial (Macromolecular Bioscience, 2023)
- The structure of cyanophycinase in complex with a cyanophycin degradation intermediate (BBA General Subjects, 2022)
- Tobacco as platform for a commercial production of cyanophycin (New Biotechnology, 2016)
- Microbial production of cyanophycin: From enzymes to biopolymers (Biotechnology Advances, 2019)
- Isolation of cyanophycin-degrading bacteria, cloning and characterization of an extracellular cyanophycinase gene (cphE) from Pseudomonas anguilliseptica strain BI (The Journal of Biological Chemistry, 2002)
- Structural bases for aspartate recognition and polymerization efficiency of cyanobacterial cyanophycin synthetase (Nature Communications, 2022)
- Cyanophycin Modifications—Widening the Application Potential (Frontiers in Bioengineering and Biotechnology, 2021)
Frequently asked questions
What is cyanophycin in simple terms?▾
Cyanophycin, also called multi-L-arginyl-poly-L-aspartate or CGP, is a polymer of two amino acids: an aspartate backbone with an arginine attached to each aspartate side chain. A 2023 review described it as a non-ribosomally made polymer that accumulates as insoluble granules inside producing bacteria (PMID 37231979). Reviewers have also discussed it as an isolable biopolymer for industrial work (PMID 31095967).
Where is cyanophycin produced?▾
It is produced by cyanobacteria and various other bacteria, where a 2023 review reported it serves as a nitrogen and carbon reserve built up and mobilised according to nutrient supply (PMID 37231979). It is also produced in engineered hosts for research and manufacturing; a 2016 study examined tobacco plants as a platform for commercial production (PMID 27501906).
Do humans make cyanophycin?▾
No human biosynthetic pathway for cyanophycin was reported in the verified literature. The polymer is described as a microbial storage compound and, in applied work, as a recombinant biomaterial produced in engineered hosts (PMID 37235756). Studies covering its enzymes focus on bacterial physiology, including one reporting that cyanophycinase is required for heterotrophy in cyanobacteria (PMID 41062069).
Which enzymes make and break cyanophycin?▾
Cyanophycin synthetase (CphA1) builds the polymer using ATP and two catalytic sites for aspartate and arginine, as reported in 2021 structural work (PMID 34385683). A separate enzyme class, CphA2, was described as a β-Asp-Arg polymerase (PMID 35179888). Cyanophycinases degrade the chain; researchers solved a cyanophycinase structure bound to a degradation intermediate (PMID 35905922).
How is cyanophycin studied in the laboratory?▾
Research has combined enzyme structural biology, microbial genetics and production chemistry. Crystallographic and related studies mapped substrate recognition and polymerisation efficiency in cyanobacterial synthetase (PMID 36042318), while a 2019 review covered microbial production from enzymes through to isolated biopolymer, including recombinant expression and recovery (PMID 31095967). Environmental turnover was studied by cloning an extracellular cyanophycinase gene (PMID 11986309).
Why do peptide readers encounter the term cyanophycin?▾
Because it is a natural peptide-bond polymer assembled without a ribosome, and because its arginine- and aspartate-rich chains interest materials researchers. A 2023 paper reported recombinant cyanophycin as an emerging biomaterial (PMID 37235756), a 2021 review reported modifications intended to widen its applications (PMID 34738009), and a 2024 study reported modified cyanophycin for tissue scaffolding (PMID 38489042).
Are there human dosing or safety studies on cyanophycin?▾
The verified papers summarised here did not report human dosing trials, protocols or adverse-event rates. They covered enzyme structures, cyanobacterial physiology and biomaterial processing, such as scaffolding-oriented modifications (PMID 38489042) and production reviews (PMID 31095967). This answer is educational only and is not medical advice; questions about health should go to a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.